List of Excipients in Branded Drug ROZEREM

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	ROZEREM	ramelteon	21695-183	COPOVIDONE
Rebel Distributors Corp	ROZEREM	ramelteon	21695-183	FERRIC OXIDE YELLOW
Rebel Distributors Corp	ROZEREM	ramelteon	21695-183	FERROSOFERRIC OXIDE
Rebel Distributors Corp	ROZEREM	ramelteon	21695-183	HYDROXYPROPYL CELLULOSE
Rebel Distributors Corp	ROZEREM	ramelteon	21695-183	HYPROMELLOSES
Rebel Distributors Corp	ROZEREM	ramelteon	21695-183	LACTOSE MONOHYDRATE
Rebel Distributors Corp	ROZEREM	ramelteon	21695-183	MAGNESIUM STEARATE

ROZEREM Excipient Strategy and Commercial Opportunities for Ramelteon

Last updated: September 16, 2026

ROZEREM, Takeda’s 8 mg ramelteon tablet, is a mature small-molecule insomnia product with limited active-ingredient patent protection and a genericized U.S. market. The strongest commercial opportunities are not in replicating the incumbent tablet alone. They are in differentiated oral delivery, excipient substitution, improved manufacturability, and regulatory pathways such as 505(b)(2) for formulations with clinical or adherence advantages.

Ramelteon is a selective melatonin MT1 and MT2 receptor agonist approved by the FDA in 2005 for insomnia characterized by difficulty with sleep onset. It is not a controlled substance and has no scheduled-drug classification in the United States (FDA, 2005).

What is the ROZEREM formulation and which excipients does it contain?

ROZEREM is an immediate-release, film-coated tablet containing 8 mg of ramelteon. The FDA-approved product uses conventional oral solid-dose excipients.

ROZEREM inactive ingredients

The FDA prescribing information identifies the core inactive ingredients as:

Formulation component	Reported role
Lactose monohydrate	Diluent and tablet mass former
Starch	Diluent, disintegrant, and processing aid
Hydroxypropyl cellulose	Binder
Magnesium stearate	Lubricant
Silicon dioxide	Glidant and flow aid

The film coating contains conventional coating materials, including hypromellose and titanium dioxide, with colorants used to provide the product’s appearance (FDA, 2005).

The formulation is commercially efficient because ramelteon has a low 8 mg dose, allowing a relatively simple direct-compression or wet-granulation platform. The primary development challenge is not tablet size. It is achieving consistent low-dose content uniformity, adequate disintegration, and reproducible dissolution across scale-up and manufacturing sites.

What technical properties matter in ramelteon excipient selection?

Excipient development should focus on four product attributes:

1. Content uniformity at the 8 mg drug load.
2. Dissolution across physiologically relevant pH conditions.
3. Chemical and physical stability during storage.
4. Robust compression, coating, packaging, and release testing.

A formulation developer should characterize ramelteon’s particle-size distribution, polymorphic form, crystallinity, bulk density, flow, electrostatic behavior, and moisture sensitivity before selecting a manufacturing route. Low-dose formulations can show blend segregation even when the active ingredient is not highly potent.

Lactose-starch systems are inexpensive and familiar to regulators. They also create opportunities for substitution where manufacturers want lactose-free, low-moisture, or directly compressible products.

What excipient substitutions create commercial opportunities for generic ramelteon?

The most accessible opportunity is a generic tablet with a lower-cost or more robust excipient system that remains therapeutically equivalent to ROZEREM.

Lactose-free ramelteon tablets

Replacing lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler may support:

• Lactose-free labeling.
• Improved moisture control.
• Better direct compression.
• Reduced variability across suppliers.
• Use in patients with lactose intolerance or sensitivity concerns.

A lactose-free claim would have commercial value only if supported by a meaningful market-access or patient-adherence strategy. Lactose in tablet quantities is generally well tolerated, so the claim alone is unlikely to command a large premium.

Co-processed excipient systems

Co-processed microcrystalline cellulose, mannitol, starch, and silica systems can improve flow and compactibility. They may reduce the need for separate binder and glidant optimization.

Potential benefits include:

• Lower tablet weight.
• Better tensile strength at lower compression force.
• Faster development of a direct-compression process.
• More consistent tablet hardness and friability.
• Reduced sensitivity to active-particle variation.

The main commercial barrier is cost. A co-processed system may be more expensive than lactose and starch. The business case depends on lower manufacturing losses, simplified processing, or a differentiated dosage form.

Superdisintegrant-enabled formulations

Sodium starch glycolate, croscarmellose sodium, and crospovidone could be evaluated to shorten disintegration time and reduce dissolution variability. The opportunity is most credible where the developer seeks:

• A rapidly disintegrating tablet.
• A smaller tablet.
• Improved performance after prolonged storage.
• A formulation suitable for modified manufacturing conditions.

A superdisintegrant does not automatically create patentable subject matter. Broad claims directed to routine use of conventional disintegrants face substantial obviousness risk unless tied to a specific composition, process, particle-size range, or performance result.

Sugar alcohol and palatability platforms

Mannitol and xylitol may support orally disintegrating or chewable ramelteon products. These excipients provide mouthfeel and can support rapid tablet dispersion.

The principal formulation risks are:

• Taste masking.
• Friability.
• Sensitivity to humidity.
• Residual mouthfeel.
• Dose uniformity during low-dose processing.

Ramelteon’s low dose makes an orally disintegrating tablet technically feasible. The commercial opportunity depends on demonstrating a clinically relevant adherence benefit for patients who have difficulty swallowing or who seek bedtime administration without water.

What formulations are protected by ROZEREM patents?

ROZEREM’s original protection centered on ramelteon as an active pharmaceutical ingredient and its therapeutic use. The commercial relevance of those rights has declined as the primary U.S. patent and regulatory exclusivity periods expired.

Patent and exclusivity position

Protection category	Historical position	Current commercial effect
New chemical entity exclusivity	FDA approval in 2005; five-year NCE period	Expired
Original compound patents	Covered ramelteon and related melatonin-receptor compounds	Expired or no longer a material barrier to ordinary U.S. generic entry
Method-of-use protection	Directed to insomnia and sleep-onset treatment concepts	Limited value after generic entry unless an unexpired, listed claim remains
Formulation patents	No widely recognized live U.S. barrier comparable to a protected extended-release platform	Opportunity remains for new, differentiated dosage forms
Manufacturing patents	Potentially available for process-specific improvements	Relevant mainly to cost, quality, and supply control

The FDA Orange Book, rather than marketing materials or patent databases alone, controls the practical analysis of listed U.S. patents and regulatory certifications. A company evaluating a specific generic filing should review the current Orange Book record, patent-listing history, and any applicable pediatric or regulatory exclusivity at the time of filing (FDA, 2024).

When did ROZEREM lose exclusivity?

ROZEREM lost its principal U.S. market exclusivity years ago. The drug was approved in 2005, and its five-year new chemical entity exclusivity expired in 2010. The key commercial patent barriers also expired before the current generic market matured.

The practical result is that a new ramelteon tablet generally competes as a conventional generic rather than as a protected branded product. Any current competitive advantage must come from formulation economics, supply reliability, dosage-form differentiation, or channel strategy.

Does ramelteon have biosimilar risk?

No. Ramelteon is a chemically synthesized small molecule, not a biologic. Biosimilar provisions under the Public Health Service Act do not apply. Competitive risk comes from ANDA-approved generic tablets, private-label products, and potential 505(b)(2) products with modified delivery systems.

Which companies are challenging ROZEREM, and what is the litigation status?

Generic ramelteon competition has included major generic manufacturers and contract manufacturers operating through ANDA pathways. The commercial record is more important than historical Paragraph IV activity because the core product is already genericized.

Paragraph IV considerations

A Paragraph IV certification would have been relevant when a generic applicant challenged an unexpired listed patent. For a mature product such as ROZEREM, the strategic value of a Paragraph IV filing is limited unless:

• A live Orange Book patent remains listed.
• The patent covers a commercially important formulation.
• The first filer can obtain meaningful 180-day exclusivity.
• The market supports litigation expense.

For a new immediate-release 8 mg tablet, the principal litigation risk is usually low. For an orally disintegrating, extended-release, multiparticulate, or pediatric formulation, patent risk shifts toward formulation and method-of-use claims.

Settlement agreements and launch restrictions

No settlement should be assumed to create a current barrier without reviewing the specific case docket and agreement. Historical generic settlements may affect individual launch dates, but they do not replace current Orange Book and ANDA status analysis.

How strong is the current ramelteon patent estate?

The estate is weak for an ordinary immediate-release tablet and potentially stronger for a genuinely differentiated delivery system.

Relative patent strength by product concept

Product concept	Patent strength	Commercial assessment
Conventional 8 mg tablet	Low	Price-driven generic competition
Lactose-free tablet	Low to moderate	Useful product attribute, limited exclusivity
Fast-disintegrating tablet	Moderate	Patentability depends on specific composition and performance
Orally disintegrating tablet	Moderate to high	Stronger if taste, disintegration, and stability are solved in combination
Extended-release ramelteon	Moderate to high	Requires pharmacokinetic and clinical justification
Pediatric liquid or multiparticulate product	Moderate	Regulatory and stability work may create entry barriers
Sublingual or buccal product	Moderate to high	Potentially differentiated, but requires clinical development
Manufacturing process improvement	Moderate	Strongest when it materially reduces cost or improves impurity control

Patent claims should focus on defined composition ranges, particle characteristics, dissolution profiles, stability results, and manufacturing parameters. A patent that merely recites known fillers in predictable amounts is vulnerable to obviousness and enablement challenges.

What 505(b)(2) opportunities exist for ramelteon?

A 505(b)(2) application could be more attractive than a standard ANDA when the product differs materially from the ROZEREM reference formulation.

Potential concepts include:

• Orally disintegrating tablets.
• Sublingual tablets or films.
• Pediatric oral liquids.
• Sprinkle capsules or granules.
• Modified-release systems.
• Fixed-dose combinations involving another sleep-related therapy.
• Formulations designed for patients with swallowing limitations.

The strongest 505(b)(2) opportunity would combine a credible clinical benefit with a formulation platform that is difficult to replicate. Examples include faster onset, lower variability, improved administration without water, or a dosage form suited to geriatric and institutional-care populations.

A modified-release product must overcome a significant commercial question: whether altering ramelteon exposure improves outcomes sufficiently to justify clinical development and a higher price. The approved product is already used for sleep-onset insomnia, which narrows the value proposition for prolonged exposure.

What manufacturing and intellectual-property barriers affect ramelteon?

Ramelteon manufacturing does not appear to be constrained by a biologic-like process barrier. The principal barriers are formulation execution, analytical control, and commercial scale.

Manufacturing risks

Key development risks include:

• Segregation of the low-dose active ingredient.
• Variable wetting or dissolution.
• Lubricant sensitivity.
• Over-lubrication and reduced tablet strength.
• Moisture-driven degradation or coating defects.
• Blend uniformity failures during scale-up.
• Supplier changes affecting excipient functionality.
• Color and coating reproducibility.

A manufacturer can create defensible know-how through blending order, granulation endpoint, screen size, compression profile, coating parameters, and packaging controls. Trade-secret protection may be more practical than patent protection for some process details.

Packaging opportunity

Blister packaging, high-barrier bottles, desiccants, and unit-dose formats can support stability and institutional distribution. Packaging is unlikely to create a large stand-alone premium, but it can reduce returns, simplify dispensing, and support adherence programs.

How does ramelteon compare with competing insomnia drugs?

Ramelteon competes with generic zolpidem, zaleplon, eszopiclone, low-dose doxepin, melatonin products, and dual orexin receptor antagonists such as suvorexant and lemborexant.

Product	Main differentiation	Generic or brand pressure	Excipient opportunity
Ramelteon	Melatonin-receptor agonist; non-controlled	High generic pressure	ODT, pediatric, lactose-free, rapid-disintegration
Zolpidem	Rapid hypnotic effect	Extensive generic competition	Modified release and sublingual systems
Eszopiclone	Sedative-hypnotic	Generic competition	Taste masking and dosage-form improvements
Doxepin	Low-dose sleep-maintenance treatment	Generic competition	Liquid and low-dose uniformity
Suvorexant	Orexin antagonist	Brand and emerging generic pressure	Formulation and combination strategies
Lemborexant	Orexin antagonist	Brand-led market	New delivery systems and lifecycle extensions
Melatonin supplements	Consumer-oriented positioning	Nonprescription competition	Gummies, liquids, and fast-dissolve formats

Ramelteon’s non-controlled status is commercially useful. It may appeal to prescribers seeking an alternative to scheduled sedative-hypnotics. That advantage does not, by itself, support a high generic price.

What is the revenue exposure and commercial opportunity?

The revenue opportunity for an ordinary ramelteon generic is limited by mature competition and low differentiation. The more attractive opportunities are segmented products with a specific channel or patient-use case.

Priority commercial segments

1. Retail generic tablets
   This is the lowest-risk development path and the most competitive market.

2. Long-term care and institutional dispensing
   Unit-dose packaging, simplified administration, and non-controlled status may improve commercial positioning.

3. Geriatric patients
   Orally disintegrating or easy-to-swallow formats could address administration barriers.

4. Pediatric sleep-onset use
   This area requires careful regulatory, clinical, and ethical analysis. A liquid or multiparticulate product could solve administration problems but would require more than an excipient-only development program.

5. International markets
   Opportunities depend on local patent status, reimbursement, approved strengths, and whether ramelteon is marketed or registered in the target jurisdiction.

6. Specialty pharmacies and adherence programs
   A differentiated dosage form can support higher gross margins if payers accept the product and the clinical benefit is documented.

A conventional generic strategy should be based on manufacturing cost, supply reliability, and regulatory speed. A differentiated strategy should be based on a clearly defined patient problem rather than excipient novelty alone.

What is the recommended excipient development strategy for ramelteon?

A staged strategy reduces technical and regulatory risk.

Stage 1: Generic-equivalent tablet

Develop a conventional immediate-release tablet using either the reference-like lactose-starch system or a direct-compression alternative. Prioritize:

• Comparative dissolution.
• Blend uniformity.
• Stability.
• Tablet robustness.
• Supplier redundancy.
• ANDA bioequivalence readiness.

Stage 2: Differentiated oral solid

Evaluate a rapidly disintegrating or orally disintegrating tablet using mannitol, crospovidone or croscarmellose sodium, and a taste-masking system if required. The target product profile should specify disintegration time, tablet strength, friability, moisture limits, and packaging configuration.

Stage 3: 505(b)(2) platform

Advance only a product with a defined clinical or adherence advantage. A 505(b)(2) program should not rely on excipient substitution alone. The product needs a new dosage form, administration route, exposure profile, or patient population with regulatory value.

Key Takeaways

• ROZEREM contains ramelteon 8 mg in a conventional immediate-release film-coated tablet.
• The core formulation uses lactose monohydrate, starch, hydroxypropyl cellulose, magnesium stearate, and silicon dioxide.
• Ramelteon’s primary U.S. exclusivity period expired long ago, and ordinary immediate-release tablets face generic competition.
• The strongest excipient opportunities are lactose-free systems, co-processed direct-compression platforms, rapidly disintegrating tablets, and orally disintegrating products.
• Biosimilar risk does not apply because ramelteon is a small molecule.
• A standard ANDA offers the lowest development risk but also the weakest pricing power.
• A 505(b)(2) strategy is more attractive for oral disintegration, pediatric administration, modified release, or another clinically meaningful delivery advantage.
• Manufacturing know-how may provide more practical value than broad formulation patents for a conventional tablet.
• Patent strength is low for a routine 8 mg tablet and potentially moderate or high for a validated differentiated delivery system.
• Commercial success depends on channel selection, supply economics, and demonstrated patient value.

FAQs

Can ramelteon be formulated as an orally disintegrating tablet?

Yes. The 8 mg dose is technically suitable for an orally disintegrating tablet. Development would need to address taste, moisture sensitivity, mechanical strength, disintegration, packaging, and bioequivalence or clinical requirements.

Is lactose-free ramelteon a strong commercial opportunity?

It is a feasible product attribute but a limited stand-alone differentiator. Its value increases when combined with direct compression, improved stability, institutional packaging, or an orally disintegrating format.

Does ramelteon require a controlled-substance handling strategy?

No. Ramelteon is not scheduled as a controlled substance in the United States. This can simplify prescribing, dispensing, and institutional inventory management compared with zolpidem and other scheduled hypnotics.

Are excipient changes enough to qualify for a 505(b)(2) application?

Usually not. Routine substitution of lactose, starch, or disintegrants generally supports an ANDA-style equivalence strategy rather than a 505(b)(2) application. A 505(b)(2) product should have a meaningful dosage-form, route, exposure, or patient-use difference.

Which excipient platform has the best patent potential?

A platform combining a defined ramelteon particle specification, a particular co-processed excipient system, controlled disintegration, and a demonstrated stability or pharmacokinetic result has stronger patent potential than a simple list of conventional excipients.

References

1. U.S. Food and Drug Administration. (2005). ROZEREM (ramelteon) tablets, prescribing information. Takeda Pharmaceuticals North America.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, ROZEREM and ramelteon product records. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Orange Book preface and patent and exclusivity information. U.S. Department of Health and Human Services.

5. National Library of Medicine. (2024). DailyMed: ROZEREM-ramelteon tablet labeling. U.S. National Library of Medicine.